These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 23647880

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia--a five-year retrospective review.
    McBride SJ, Upton A, Roberts SA.
    Eur J Clin Microbiol Infect Dis; 2010 Jan; 29(1):107-14. PubMed ID: 19916034
    [Abstract] [Full Text] [Related]

  • 3. Microbiological and clinical characteristics of vancomycin-resistant Enterococcus faecium bacteraemia in Taiwan: implication of sequence type for prognosis.
    Lu CL, Chuang YC, Chang HC, Chen YC, Wang JT, Chang SC.
    J Antimicrob Chemother; 2012 Sep; 67(9):2243-9. PubMed ID: 22618861
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Enterococcal bacteraemia: predictive and prognostic risk factors for ampicillin resistance.
    Matsumura T, Nagao M, Nakano S, Yamamoto M, Matsumura Y, Ichiyama S.
    Epidemiol Infect; 2018 Dec; 146(16):2028-2035. PubMed ID: 30165917
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Study of a cohort of patients with Enterococcus spp. Bacteraemia. Risk factors associated to high-level resistance to aminoglycosides].
    García-Vázquez E, Albendín H, Hernández-Torres A, Canteras M, Yagüe G, Ruiz J, Gómez J.
    Rev Esp Quimioter; 2013 Sep; 26(3):203-13. PubMed ID: 24080886
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Vancomycin-resistant enterococcal bacteremia: comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis.
    Chou YY, Lin TY, Lin JC, Wang NC, Peng MY, Chang FY.
    J Microbiol Immunol Infect; 2008 Apr; 41(2):124-9. PubMed ID: 18473099
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).
    Mohr JF, Friedrich LV, Yankelev S, Lamp KC.
    Int J Antimicrob Agents; 2009 Jun; 33(6):543-8. PubMed ID: 19201165
    [Abstract] [Full Text] [Related]

  • 15. Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia in cancer patients.
    Conde-Estévez D, Grau S, Albanell J, Terradas R, Salvadó M, Knobel H.
    Eur J Clin Microbiol Infect Dis; 2011 Jan; 30(1):103-8. PubMed ID: 20711795
    [Abstract] [Full Text] [Related]

  • 16. Identification of temporal clusters and risk factors of bacteremia by nosocomial vancomycin-resistant enterococci.
    da Silva NS, Muniz VD, Estofolete CF, Furtado GH, Rubio FG.
    Am J Infect Control; 2014 Apr; 42(4):389-92. PubMed ID: 24679566
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.